Drug Information
Drug (ID: DG00439) and It's Reported Resistant Information
| Name |
Thiopurine
|
||||
|---|---|---|---|---|---|
| Synonyms |
2-Mercaptopurine; 2-Thiopurine; 28128-19-0; 5-Mercaptopurine; Purine-2-thiol; 3,7-dihydropurine-2-thione; Thiopurine; UNII-81XK02929C; 81XK02929C; 2-Purinethiol; 7H-purine-2-thiol; 1,3-Dihydro-2H-purine-2-thione; 2-MP; 3,7-dihydro-2H-purine-2-thione; EINECS 248-855-0; NSC 23720; 2H-Purine-2-thione, 1,3-dihydro-; SCHEMBL3896; DTXSID60878767; NSC23720; MFCD00047145; NSC-23720; ZINC12955987; AKOS006275100; 2-Mercaptopurine, >=95%, crystalline; 2H-Purine-2-thione, 1,3-dihydro- (9CI); FT-0694524; W-202176; Q27269279
Click to Show/Hide
|
||||
| Structure |
|
||||
| Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Acute lymphocytic leukemia [ICD-11: 2B33]
[1]
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| Formula |
C5H4N4S
|
||||
| IsoSMILES |
C1=NC(=S)NC2=C1NC=N2
|
||||
| InChI |
1S/C5H4N4S/c10-5-6-1-3-4(9-5)8-2-7-3/h1-2H,(H2,6,7,8,9,10)
|
||||
| InChIKey |
HDBQZGJWHMCXIL-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Type(s) of Resistant Mechanism of This Drug
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Acute lymphocytic leukemia [ICD-11: 2B33]
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | |||||||||||||
|
Unusual Activation of Pro-survival Pathway (UAPP)
|
|||||||||||||
| Key Molecule: Cytosolic purine 5'-nucleotidase (NT5C2) | [1] | ||||||||||||
| Resistant Disease | Acute lymphocytic leukemia [ICD-11: 2B33.0] | ||||||||||||
| Molecule Alteration | Missense mutation | p.R238W |
|||||||||||
| Wild Type Structure | Method: X-ray diffraction | Resolution: 1.70 Å | |||||||||||
| Mutant Type Structure | Method: X-ray diffraction | Resolution: 1.84 Å | |||||||||||
| Download The Information of Sequence | Download The Structure File | ||||||||||||
-
-
M
-
G
-
S
-
S
-
H
-
H
-
H
-
H
-10
|
-
H
-
H
-
S
-
S
-
G
-
L
-
V
-
P
-
R
-
G
0
|
-
S
-
M
-
S
T
T
S
S
W
W
S
S
D
D
R
R
L
L
10
|
Q
Q
N
N
A
A
A
A
D
D
M
M
P
P
A
A
N
N
M
M
20
|
D
D
K
K
H
H
A
A
L
L
K
K
K
K
Y
Y
R
R
R
R
30
|
E
E
A
A
Y
Y
H
H
R
R
V
V
F
F
V
V
N
N
R
R
40
|
S
S
L
L
A
A
M
M
E
E
K
K
I
I
K
K
C
C
F
F
50
|
G
G
F
F
D
D
M
M
D
D
Y
Y
T
T
L
L
A
A
V
V
60
|
Y
Y
K
K
S
S
P
P
E
E
Y
Y
E
E
S
S
L
L
G
G
70
|
F
F
E
E
L
L
T
T
V
V
E
E
R
R
L
L
V
V
S
S
80
|
I
I
G
G
Y
Y
P
P
Q
Q
E
E
L
L
L
L
S
S
F
F
90
|
A
A
Y
Y
D
D
S
S
T
T
F
F
P
P
T
T
R
R
G
G
100
|
L
L
V
V
F
F
D
D
T
T
L
L
Y
Y
G
G
N
N
L
L
110
|
L
L
K
K
V
V
D
D
A
A
Y
Y
G
G
N
N
L
L
L
L
120
|
V
V
C
C
A
A
H
H
G
G
F
F
N
N
F
F
I
I
R
R
130
|
G
G
P
P
E
E
T
T
R
R
E
E
Q
Q
Y
Y
P
P
N
N
140
|
K
K
F
F
I
I
Q
Q
R
R
D
D
D
D
T
T
E
E
R
R
150
|
F
F
Y
Y
I
I
L
L
N
N
T
T
L
L
F
F
N
N
L
L
160
|
P
P
E
E
T
T
Y
Y
L
L
L
L
A
A
C
C
L
L
V
V
170
|
D
D
F
F
F
F
T
T
N
N
C
C
P
P
R
R
Y
Y
T
T
180
|
S
S
C
C
E
E
T
T
G
G
F
F
K
K
D
D
G
G
D
D
190
|
L
L
F
F
M
M
S
S
Y
Y
R
R
S
S
M
M
F
F
Q
Q
200
|
D
D
V
V
R
R
D
D
A
A
V
V
D
D
W
W
V
V
H
H
210
|
Y
Y
K
K
G
G
S
S
L
L
K
K
E
E
K
K
T
T
V
V
220
|
E
E
N
N
L
L
E
E
K
K
Y
Y
V
V
V
V
K
K
D
D
230
|
G
G
K
K
L
L
P
P
L
L
L
L
L
L
S
S
R
W
M
M
240
|
K
K
E
E
V
V
G
G
K
K
V
V
F
F
L
L
A
A
T
T
250
|
N
N
S
S
D
D
Y
Y
K
K
Y
Y
T
T
D
D
K
K
I
I
260
|
M
M
T
T
Y
Y
L
L
F
F
D
D
F
F
P
P
H
H
G
G
270
|
P
P
K
K
P
P
G
G
S
S
S
S
H
H
R
R
P
P
W
W
280
|
Q
Q
S
S
Y
Y
F
F
D
D
L
L
I
I
L
L
V
V
D
D
290
|
A
A
R
R
K
K
P
P
L
L
F
F
F
F
G
G
E
E
G
G
300
|
T
T
V
V
L
L
R
R
Q
Q
V
V
D
D
T
T
K
K
T
T
310
|
G
G
K
K
L
L
K
K
I
I
G
G
T
T
Y
Y
T
T
G
G
320
|
P
P
L
L
Q
Q
H
H
G
G
I
I
V
V
Y
Y
S
S
G
G
330
|
G
G
S
S
S
S
D
D
T
T
I
I
C
C
D
D
L
L
L
L
340
|
G
G
A
A
K
K
G
G
K
K
D
D
I
I
L
L
Y
Y
I
I
350
|
G
G
D
D
H
H
I
I
F
F
G
G
D
D
I
I
L
L
K
K
360
|
S
S
K
K
K
K
R
R
Q
Q
G
G
W
W
R
R
T
T
F
F
370
|
L
L
V
V
I
I
P
P
E
E
L
L
A
A
Q
Q
E
E
L
L
380
|
H
H
V
V
W
W
T
T
D
D
K
K
S
S
S
S
L
L
F
F
390
|
E
E
E
E
L
L
Q
Q
S
S
L
L
D
D
I
I
F
F
L
L
400
|
A
A
E
E
L
L
Y
Y
K
K
H
H
L
L
D
D
S
S
S
S
410
|
S
S
N
N
E
E
R
R
P
P
D
D
I
I
S
S
S
S
I
I
420
|
Q
Q
R
R
R
R
I
I
K
K
K
K
V
V
T
T
H
H
D
D
430
|
M
M
D
D
M
M
C
C
Y
Y
G
G
M
M
M
M
G
G
S
S
440
|
L
L
F
F
R
R
S
S
G
G
S
S
R
R
Q
Q
T
T
L
L
450
|
F
F
A
A
S
S
Q
Q
V
V
M
M
R
R
Y
Y
A
A
D
D
460
|
L
L
Y
Y
A
A
A
A
S
S
F
F
I
I
N
N
L
L
L
L
470
|
Y
Y
Y
Y
P
P
F
F
S
S
Y
Y
L
L
F
F
R
R
A
A
480
|
A
A
H
H
V
V
L
L
M
M
P
P
H
H
E
E
S
S
-
T
490
|
-
V
-
E
-
H
-
T
-
H
-
V
-
D
-
I
-
N
-
E
500
|
-
M
-
E
-
S
-
P
-
L
-
A
-
T
-
R
-
N
-
R
510
|
-
T
-
S
-
V
-
D
-
F
-
K
-
D
-
T
-
D
-
Y
520
|
-
K
-
R
-
H
-
Q
-
L
-
T
-
R
-
S
-
I
-
S
530
|
-
E
-
I
-
K
-
P
-
P
-
N
-
L
|
|||||||||||||
| Experimental Note | Identified from the Human Clinical Data | ||||||||||||
| Experiment for Molecule Alteration |
Whole-exome sequencing assay; Whole-genome sequencing assay | ||||||||||||
| Experiment for Drug Resistance |
Flow cytometric analysis assay; MTT assay | ||||||||||||
| Mechanism Description | Finally, genomic profiling of diagnostic and relapsed leukemias has identified relapse-associated mutations in the 5'-nucleotidase, cytosolic II(NT5C2) gene as drivers of resistance to thiopurine chemotherapy in about 20% of T-ALL and 5% of B-precursor ALL cases at relapse. | ||||||||||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.